Disitamab’s launch time, approval progress and analysis of domestic and foreign drug purchase channels

Vedicitumab (Disitamab) is a monoclonal antibody conjugate drug targeting HER2. It is mainly used for the treatment of HER2 positive advanced or metastatic gastric cancer, breast cancer and other indications. By binding to the HER2 receptor and releasing cytotoxic drugs, the drug achieves precise killing of tumor cells while reducing damage to normal tissues. The launch of vedicitomab marks a new breakthrough in the field of anti-HER2 targeted therapy in China, providing more treatment options for HER2-positive patients.

In terms of time to market and approval progress, vedicitomab has been approved for marketing in China and has been included in the medical insurance reimbursement catalog, allowing patients to obtain standardized treatment in hospitals. The drug has shown good efficacy and safety in clinical trials, especially in HER2-positive patients who have relapsed or metastasized despite previous standard treatment, showing significant tumor remission effects. In overseas markets, the approval and marketing status of Vidicitomab is different from that in China. Some regions are still in the clinical trial or approval stage, and purchase channels are limited.

In terms of domestic drug purchase channels, since vedicitomab has been included in the medical insurance project, patients can purchase it directly through oncology departments or pharmacies in various hospitals. The price is relatively controllable, and the cost of each treatment is less than 3000 RMB. The medical insurance reimbursement policy can adjust the self-payment ratio according to the patient's location and medical insurance type, helping to reduce the financial burden. Patients are required to provide a doctor's prescription when purchasing drugs and follow hospital management regulations to ensure safe and standardized use of drugs.

Overseas drug purchase channels mainly rely on clinical trials or legal imported drug channels, and some countries have not yet fully approved marketing. If patients consider obtaining vedicitomab through overseas channels, they need to pay attention to the legality, transportation conditions and price of the drug. Overall, the domestic listing and inclusion in medical insurance give Vidicitomab a significant advantage in treatment accessibility. Patients can obtain the drug through regular hospital channels and enjoy the support of medical insurance policies, allowing for safer and more convenient targeted therapy.

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/